Key points
- FY2027 revenue guidance of $105 million - $115 million
- Expected growth of 42% - 55% on FY2026
- Adjusted EBITDA margin guidance of 23% - 26%
Full summary
BLS Pharmaceuticals Ltd (ASX:BLS) has released its FY2027 revenue guidance, projecting a range of $105 million to $115 million. This represents a growth of approximately 42% to 55% over the FY2026 revenue of $74.2 million. The company anticipates an Adjusted EBITDA margin of 23% to 26%. BLS is entering FY2027 from a strong position following its transformation into an international pharmaceutical manufacturer in FY2026. The company expects continued demand in Australia, with significant available manufacturing capacity. BLS also plans to execute existing international contracts, including a two-year A$50 million supply agreement with ADREXpharma in Germany. Additionally, BLS is constructing a new GMP production site in the Scottish Borders, which is expected to complete by the end of 2026 and provide manufacturing capacity for the UK and international markets.
Guidance
FY2027 revenue guidance of $105 million - $115 million, Adjusted EBITDA margin of 23% - 26%
Outlook
BLS Pharmaceuticals Ltd expects continued growth and demand in Australia and internationally, supported by its expanded manufacturing capacity and international contracts.